The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of aggressive combined-modality primary therapy in anaplastic thyroid carcinoma (ATC): An updated single-institution experience.
Naiyarat Prasongsook
No relevant relationships to disclose
Robert Leonard Foote
No relevant relationships to disclose
Julian R. Molina
No relevant relationships to disclose
Jan C. Kasperbauer
No relevant relationships to disclose
Yolanda I. Garces
No relevant relationships to disclose
Daniel Ma
No relevant relationships to disclose
Joseph Rubin
No relevant relationships to disclose
Ronald L. Richardson
No relevant relationships to disclose
Ian D. Hay
No relevant relationships to disclose
Vahab Fatourechi
No relevant relationships to disclose
Bryan McIver
No relevant relationships to disclose
John C. Morris
No relevant relationships to disclose
Geoffrey B. Thompson
No relevant relationships to disclose
Clive S. Grant
No relevant relationships to disclose
Melanie L. Richards
No relevant relationships to disclose
Vera J. Suman
No relevant relationships to disclose
Keith Christopher Bible
No relevant relationships to disclose